Axa S.A. Coherus Bio Sciences, Inc. Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $539,696 - $1.18 Million	142,400 New	142,400 $608,000
Q1 2019 May 14, 2019	SELL	$8.38 - $15.5 $492,568 - $911,074	-58,779 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$8.65 - $16.28 $3.03 Million - $5.7 Million	-350,104 Reduced 85.62%	58,779 $532,000
Q2 2018 Aug 13, 2018	BUY	$10.25 - $17.45 $53,330 - $90,792	5,203 Added 1.29%	408,883 $5.72 Million
Q1 2018 May 14, 2018	SELL	$9.1 - $13.7 $36,163 - $54,443	-3,974 Reduced 0.97%	403,680 $4.46 Million
Q4 2017 Feb 13, 2018	SELL	$8.35 - $14.4 $3,390 - $5,846	-406 Reduced 0.1%	407,654 $3.59 Million
Q3 2017 Nov 13, 2017	BUY	$11.1 - $14.5 $4.53 Million - $5.92 Million	408,060	408,060 $5.45 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.